Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Receives Average Rating of “Moderate Buy” from Brokerages

Posted by Renee Jackson on Nov 4th, 2025

Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) have been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $4.75.

A number of research firms have commented on ADIL. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a research report on Saturday, July 26th. Zacks Research lowered shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Maxim Group upgraded Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Tuesday, September 30th.

Get Our Latest Stock Analysis on Adial Pharmaceuticals

Adial Pharmaceuticals Price Performance

ADIL opened at $0.35 on Tuesday. Adial Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $1.30. The stock has a market cap of $7.53 million, a P/E ratio of -0.33 and a beta of 1.32. The stock’s 50 day moving average price is $0.36 and its 200 day moving average price is $0.45.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Equities analysts anticipate that Adial Pharmaceuticals will post -1.53 EPS for the current year.

Adial Pharmaceuticals Company Profile

(Get Free Report)

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.